RxDoctor Payments Data

Darren Adderly, MD

Internal Medicine · Tampa, FLNPI 1386904522

Payments from drug & device makers

$748in general payments, 2019–2025

Across 21 payments — averaging $35.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$186
  • Johnson & Johnson$153
  • Otsuka America Pharmaceutical, Inc.$111
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$83
  • Teva Pharmaceuticals USA, Inc.$38
  • E.r. Squibb & Sons, L.L.C.$35
  • plus $142 from 6 others

What the payments were for

  • Food & beverage$748100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$748 in reported general payments places this provider in the 60th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$262,728
Medicare patients
655
Services billed
2,552

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate34$83,873
EliquisApixaban132$42,032
XareltoRivaroxaban58$17,131
FarxigaDapagliflozin Propanediol33$11,087
Budesonide36$6,990
Mirtazapine203$6,588
Carbidopa11$5,646
PradaxaDabigatran Etexilate Mesylate25$4,089
Duloxetine Hcl109$3,814
Atorvastatin Calcium275$3,779
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog15$3,681
Divalproex Sodium108$3,618
Fiasp FlextouchInsulin Aspart (Niacinamide)15$3,389
Entacapone15$3,364
Cyclosporine17$3,336

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$34$83,87334 claims
Johnson & JohnsonXarelto$153$17,13158 claims
AstraZenecaFarxiga$20$11,08733 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →